A patient treated with total thyroidectomy and radioiodine for papillary thyroid carcinoma has a rising stimulated thyroglobulin, confirmed on repeat testing with the same assay; anti-thyroglobulin antibodies are absent. Neck ultrasound is negative and diagnostic radioiodine imaging shows no avid disease. What is the best next investigation principle?
Confirmed antibody-negative biochemical recurrence with negative ultrasound and iodine imaging suggests occult or dedifferentiated disease; risk-adapted CT/MRI and FDG PET can localise disease for directed treatment.
A. Give another empiric radioiodine dose before anatomical localisation: Non-avid disease may not respond, and further treatment should be risk- and imaging-led rather than automatic.
B. Cross-sectional and/or FDG PET imaging guided by risk and tumour-marker level: Confirmed antibody-negative biochemical recurrence with negative ultrasound and iodine imaging suggests occult or dedifferentiated disease; risk-adapted CT/MRI and FDG PET can localise disease for directed treatment.
C. Undertake bilateral compartment neck dissection despite negative localisation: Surgery without a structural target creates morbidity and may miss distant or unresectable disease.
D. Use a different thyroglobulin assay once and act on any lower result: Inter-assay variation can create a false trend; longitudinal interpretation should use the same validated assay.
E. Suppress TSH further and omit structural reassessment: TSH suppression may be part of risk management but does not localise a credible rising marker.
If thyroglobulin were undetectable but anti-thyroglobulin antibodies were rising, antibody trend and assay interpretation would drive surveillance rather than treating the thyroglobulin value as reliable.
Independent Clinora educational material; not official JCIE content, an accredited programme, clinical advice, or a substitute for local policy and specialist judgement.
Back to the Section 1 bank